International Cancer Patient Coalition

Egypt

Breast Cancer Factsheet: Insights & Key Developments

Key Insights on Breast Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Breast Cancer Screening

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping breast cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Breast cancer incidence: 32.4% of all female cancers.
- Incidence rate: 48.8 per 100,000 women.
- Total cases: Approximately 26,845 new cases reported.
- Daily diagnoses: Approximately 74 new cases per day.
- Breast cancer deaths : Approximately 9,148 deaths.
- Most affected age group: Median age at diagnosis is 51 years; approximately 19% of cases are aged ≤40 years.

International Cancer Patient Coalition

Egypt

Infrastructure



Strengths

- Specialized cancer centers like NCI Cairo and 57357 Hospital are highly developed.
- HER2, ER, PR, and BRCA testing available in major cities.

Weakness

- Limited diagnostic infrastructure in rural areas.
- High costs restrict access to advanced testing outside urban centers.

S W O T

Opportunity

- Decentralize testing capabilities and improve training in secondary hospitals.
- Leverage international collaborations to strengthen technology transfer.

Threats

- Urban–rural divide threatens equitable access.
- Infrastructure gaps may delay implementation of national cancer strategies.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	2	2
Nigeria	2	2
Egypt	3	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	3
Japan	4	4
South Korea	4	4
China	3	3
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	5
France	4	4
Netherlands	5	5
Sweden	5	5
Italy	4	4
Spain	4	4
Poland	3	3
Mexico	2	2
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	2
United States	5	5
Canada	5	5
Australia	4	4
New Zealand	4	4
Greece	3	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	3	3
UAE	3	4
Syria	1	1
Indonesia	2	2
Vietnam	2	2
Philippines	2	2
Russia	4	3

International Cancer Patient Coalition

Egypt

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Advanced treatment options available in major hospitals (e.g., NCI, Baheya).
- Awareness campaigns like “100 Million Healthy Lives” have broad reach.

Weakness

- Only ~40% of patients receive timely treatment.
- Breast cancer receives <5% of medical research funding.

S W O T

Opportunity

- Expand national insurance and early detection programs to underserved areas.
- Mobilize private sector and NGOs to enhance outreach.

Threats

- Out-of-pocket costs exceed 60%, limiting access.
- Inadequate funding may stall clinical trials and innovation.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	2	2	2
Nigeria	2	2	2
Egypt	3	3	3
Morocco	2	2	3
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	4
South Korea	4	4	4
China	3	4	3
Thailand	3	3	3
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	5	5
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	2	3
Brazil	3	3	3
Argentina	3	3	3
Chile	2	3	3
Colombia	2	2	3
United States	5	5	5
Canada	5	5	5
Australia	4	4	5
New Zealand	4	4	4
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	3	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	2	1	1
Indonesia	3	2	3
Vietnam	3	2	3
Philippines	3	2	3
Russia	4	4	3

International Cancer Patient Coalition

Egypt

Survival Rates, Early Detection and Palliative Care



Strengths

- Five-year survival rate improving (~65%).
- National screening campaigns increasing early-stage diagnoses.

Weakness

- Palliative care infrastructure limited outside Cairo and Alexandria.
- Mammography access remains inconsistent in rural areas.

S W O T

Opportunity

- Integrate palliative care into primary care and cancer centers.
- Expand mobile screening units and early detection outreach.

Threats

- Rural populations remain at high risk for late-stage diagnosis.
- Unequal access to pain management and end-of-life care.

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	3	3	3
Kenya	2	2	2
Nigeria	2	1	2
Egypt	3	3	3
Morocco	3	3	3
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	4
South Korea	4	4	4
China	3	3	3
Thailand	3	3	3
Singapore	4	5	4
United Kingdom	4	5	4
Germany	5	5	5
France	4	5	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	2
Brazil	3	3	3
Argentina	3	3	3
Chile	2	3	3
Colombia	2	3	2
United States	5	5	5
Canada	5	5	4
Australia	4	4	4
New Zealand	4	4	4
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	3	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	2	2	1
Indonesia	3	3	2
Vietnam	3	3	2
Philippines	3	3	3
Russia	4	3	3

International Cancer Patient Coalition

Egypt

Utilization of Biomarkers



Strengths

- HER2, ER, and PR testing routinely available in major hospitals.
- Personalized treatment pathways increasingly used in urban centers.

Weakness

- BRCA testing limited to private hospitals and research institutions.
- Cost is a major barrier for comprehensive testing in public care.

S W O T

Opportunity

- Expand national biomarker testing programs and subsidies.
- Integrate genetic counseling and molecular diagnostics across regions.

Threats

- Out-of-pocket costs deter broad uptake.
- Lack of reimbursement may slow adoption of precision medicine.

5. 80% Biomarker testing is widely available and routinely performed as part of standard clinical practice. Strong integration into treatment decisions, with national coverage and reimbursement ensuring accessibility.

4. 61-80%. Biomarker testing is commonly used, but access may be limited in certain regions or patient groups. Some disparities exist in coverage or affordability, but it is still a crucial part of cancer diagnostics

3. 41-60% Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

2. 20-40% Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

1. <20% Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

Egypt

Clinical Guidelines



Strengths

- National protocols align with ESMO/NCCN guidelines.
- Strong adoption in leading hospitals with access to training.

Weakness

- Implementation uneven in rural and smaller facilities.
- Resource limitations hinder real-time updates and dissemination.

S W O T

Opportunity

- Use digital tools and CME platforms to spread guideline access.
- Customize global recommendations to Egypt's local realities.

Threats

- Inconsistent application of standards reduces care quality.
- Limited staff training may stall nationwide harmonization.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	✖	○	✖	✖	✖
Feasibility of Integration	✖	✖	○	✖	✖
Adoption of International Guidelines	✖	✖	○	✖	✖
Engagement with Updates	✖	✖	✖	○	✖
ESMO Guidelines Implementation	✖	✖	○	✖	✖

International Cancer Patient Coalition

Egypt

Reimbursement

Strengths

- UHIS and public sector programs offer partial to full coverage.
- Free chemotherapy and radiation available in government hospitals.

Weakness

- Patients often pay out-of-pocket for targeted therapies and diagnostics.
- Innovative treatments (e.g., immunotherapies) not widely covered.

S W O T

Opportunity

- Expand coverage of advanced therapies under UHIS.
- Strengthen partnerships to improve affordability.

Threats

- Financial burden remains high for uninsured or underinsured.
- Delayed rollout of full UHIS may slow equitable access.

O A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

O A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

✖ No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement	No-cost Access
South Africa	O	✖
Kenya	✖	✖
Nigeria	✖	✖
Egypt	O	O
Morocco	O	✖
Algeria	O	✖
Ethiopia	✖	✖
India	O	✖
Japan	O	O
South Korea	O	O
China	O	O
Thailand	O	O
Singapore	O	O
United Kingdom	O	O
Germany	O	O
France	O	O
Netherlands	O	O
Sweden	O	O
Italy	O	O
Spain	O	O
Poland	O	O
Mexico	O	✖
Brazil	O	✖
Argentina	O	✖
Chile	O	O
Colombia	O	✖
United States	O	O
Canada	O	O
Australia	O	O
New Zealand	O	O
Greece	O	O
Rwanda	✖	✖
Uganda	✖	✖
Serbia	O	O
Saudi Arabia	O	O
UAE	O	O
Syria	O	O
Indonesia	O	O
Vietnam	✖	✖
Philippines	✖	✖
Russia	O	O

International Cancer Patient Coalition

Egypt

Breast Cancer Screening

Strengths

- "100 Million Healthy Lives" offers free screening for women 40+.
- Clinical breast exams and mammograms conducted at primary health units.

Weakness

- Screening participation and consistency vary across regions.
- Rural and underserved areas still face barriers to access.



Opportunity

- Scale up NGO involvement and integrate mobile units.
- Use community health workers to increase awareness and participation.

Threats

- Lack of national standardization limits effectiveness.
- Underdiagnosis in high-risk populations could persist without expanded access.

Country	Breast Cancer Screening
United States	Biennial mammograms (50-74 years)
United Kingdom	Triennial mammograms (50-71 years)
Canada	Mammograms every 2-3 years (50-74 years)
Australia	Biennial mammograms (50-74 years)
Germany	Mammograms every 2 years (50-69 years)
France	Biennial mammograms (50-74 years)
Netherlands	Mammograms every 2 years (50-75 years)
Sweden	Mammograms every 18-24 months (40-74 years)
Italy	Mammograms every 2 years (50-69 years)
Spain	Mammograms every 2 years (50-69 years)
Poland	Mammograms every 2 years (50-69 years)
Japan	Mammograms every 2 years (40+ years)
South Korea	Biennial mammograms (40+ years)
China	Regional mammogram programs (40-69 years)
India	Opportunistic screening
Singapore	Biennial mammograms (50-69 years)
Saudi Arabia	Opportunistic screening; regional programs for women aged 40+
UAE	Opportunistic screening; encouraged every 2 years for 40-69 years
Syria	No national program; limited local initiatives due to conflict

Country	Breast Cancer Screening
Thailand	Biennial mammograms (50-69 years)
South Africa	Opportunistic screening
Kenya	No national program
Nigeria	No national program
Egypt	National awareness campaigns
Morocco	National program for 45-69 years
Algeria	Planned national program (50-69 years)
Ethiopia	No national program
Mexico	Biennial mammograms (40-69 years)
Brazil	Biennial mammograms (50-69 years)
Argentina	Biennial mammograms (50-69 years)
Chile	Mammograms every 3 years (50-69 years)
Colombia	Biennial mammograms (50-69 years)
New Zealand	Biennial mammograms (45-69 years)
Greece	Biennial mammograms (50-69 years)
Rwanda	No national program
Uganda	No national program
Serbia	Biennial mammograms (50-69 years)
Indonesia	Opportunistic screening; no national mammography program
Vietnam	Regional mammography programs; pilot programs in urban areas (age 45–69)
Philippines	Opportunistic screening; mammography recommended every 2 years for women 50+
Russia	National program for biennial mammograms (50–69 years)